Manilatimes

Published October 5, 2026

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the ...

Read the full story at Manilatimes

ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET Orion ... MAPS and International Alliance of Psychedelic Therapy Practitioners Announce.